Developing better gene editing technology

David Bergstrom, CRISPR

CRISPR/Cas9 technologies have transformed the process of creating new mouse models of human diseases, reducing the time, cost and effort to incorporate specific mutations in mice. To further develop a unique combination of technologies (called CRISPR/BAC/HR) that will enable the precise editing of longer segments of DNA, the National Institutes of Health have awarded a two-year exploratory grant totaling $466,875 to Jackson Laboratory (JAX) Research Scientist David Bergstrom, Ph.D.

Working with Charles Lee, Ph.D., professor and scientific director of JAX Genomic Medicine, and JAX Research Assistant Tiffany Leidy-Davis, Bergstrom plans to use the CRISPR/BAC/HR technology to develop mouse models for gastric cancer, Down syndrome and other applications.

Want to hear the latest from JAX? Subscribe to our newsletters!

Thanks for reading articles from JAX!

Subscribe to our newsletters for the latest news!